Drugs / ATG
last change Feb 2026 re-read 2 minutes ago

ATG

Developed for
chronic myelomonocytic leukemia
Investigated by
Peking University People's Hospital

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT07588594 Feb 2026 → May 2028 expected chronic myelomonocytic leukemia Peking University People's Hospital Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ATG ATG per donor type (haplo/unrelated: 2.5 mg/kg/d days -5 to -2; MSD: 1.125 mg/kg/d days -5 to -2)” NCT07588594